TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02104284

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: methacholine and mannitol bronchial challenge tests
Description: Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: methacholine and mannitol bronchial challenge tests
Description: Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: methacholine and mannitol bronchial challenge tests
Description: Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis.
Study: NCT02998112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: Fecal microbiota which was purified from fresh stool defecated by a healthy donor
Study: NCT01591785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retapamulin 1% ointment
Description: Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
Study: NCT02998112

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02371811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uterine manipulator (v care)
Study: NCT04526054

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ENT exam
Description: ENT examination of the nasal cavity: nasofibroscopy and anterior rhinoscopy.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Olfactometry
Description: Olfactometry test using odorous pens (Sniffin's stick test).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Brain MRI
Description: Brain MRI focused on the olfactory bulbs (3 teslas).
Study: NCT01160614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride controlled-release (ORF) tablets
Description: Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
Study: NCT04145817

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BRIDGES gene panel testing
Description: The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium.
Study: NCT03370705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statin 20mg once daily per oral route,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Agents
Description: Antiplatelet therapy 75mg once daily per oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Agents
Description: Antiplatelet therapy 75mg once daily per oral route
Study: NCT04145817

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Breast cancer risk polygenic risk score (PRS)
Description: The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium.
Study: NCT02409693

Intervention type: PROCEDURE
Intervention: Myringotomy with tube insertion
Study: NCT03136666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil
Description: Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
Study: NCT02140060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Level A / Brinzolamide 1% ophthalmic suspension
Description: Fixed combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Level B / Brinzolamide 1% ophthalmic suspension
Description: Fixed combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Level C / Brinzolamide 1% ophthalmic suspension
Description: Fixed combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 1% ophthalmic suspension AZOPT®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 1% ophthalmic suspension AZOPT®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004% ophthalmic solution TRAVATAN Z®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004% ophthalmic solution TRAVATAN Z®
Study: NCT04145817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Self-administered questionnaires for counselees to evaluate Psychosocial Aspects of Hereditary Cancer (PAHC), Breast Cancer risk perception adequacy, risk communication within the family and cancer risk management choice,
Study: NCT00780832

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Caffeine reduction
Description: Participants are counseled about reduction of dietary caffeine, given written information and a bladder control log.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic medication
Description: Detrol LA 4mg. orally, once daily for 30 days
Study: NCT02812043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1,064nm Long-pulsed Nd:YAG
Description: Long-pulsed 1,064nm will be used for the treatment of onychomycosis which wll use 35-45 J/cm2 spot size 4, frequency 1 Hz for 2 passes on the infected nails

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1,064nm Long-pulsed Nd:YAG
Description: Long-pulsed 1,064nm will be used for the treatment of onychomycosis which wll use 35-45 J/cm2 spot size 4, frequency 1 Hz for 2 passes on the infected nails
Study: NCT02140060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost solution vehicle
Description: Inactive ingredients used for masking purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost solution vehicle
Description: Inactive ingredients used for masking purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost solution vehicle
Description: Inactive ingredients used for masking purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost solution vehicle
Description: Inactive ingredients used for masking purposes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide suspension vehicle
Description: Inactive ingredients used for masking purposes
Study: NCT02812043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amorolfine
Description: Amorolfine nail lacquer will be applied by the patient once a week on the infected nails

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amorolfine
Description: Amorolfine nail lacquer will be applied by the patient once a week on the infected nails
Study: NCT01448798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of a hemostatic gelatin-thrombin matrix
Description: Hemostatic gelatin-thrombin matrix is used for hemostasis during nerve-sparing dissection of the prostate.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Use of mono- and bipolar electrocautery and surgical clips
Description: Mono- and bipolar electrocautery and surgical clips are used for hemostasis during nerve-sparing dissection of the prostate.
Study: NCT02763865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil
Description: Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.~Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output.
Study: NCT03370705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: ACE inhibitor 20mg once daily per oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Description: ACE inhibitor 20mg once daily per oral route
Study: NCT03537300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DCF muscles training using pressure biofeedback in addition to conventional exercises
Description: DCF muscles training using pressure biofeedback in addition to conventional exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional exercises
Description: conventional exercises
Study: NCT02745730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Study: NCT02763865

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: eSHAM system
Description: implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)
Study: NCT02745730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allulose
Study: NCT02104284

Intervention type: PROCEDURE
Group type: OTHER
Intervention: methacholine and mannitol bronchial challenge tests
Description: Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis.
Study: NCT04455711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Iv
Description: Bolus dose of 1.5 mg/kg lidocaine was injected immediate after operation.
Study: NCT04765631

Intervention type: OTHER
Intervention: Patients with Type 2 diabetes
Description: No intervention
Study: NCT03536130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic chest drainage system
Description: Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter. Management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms and surgeon preference following standard clinical practice of general thoracic patients
Study: NCT03063047

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21871AA
Description: A 100s size menthol cigarette.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21871AA
Description: A 100s size menthol cigarette.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21872AA
Description: A 100s size menthol cigarette.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21872AA
Description: A 100s size menthol cigarette.
Study: NCT04765631

Intervention type: OTHER
Intervention: Placebo
Description: Placebo comparator
Study: NCT00486811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100 to 250 mg twice daily)
Description: 50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (twice daily)
Description: Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR (20 to 50 mg twice daily)
Description: 10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
Study: NCT00926315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: calcitriol 0.25 mcg PO bid
Study: NCT02919358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music

Intervention type: OTHER
Group type: OTHER
Intervention: No music.
Description: This is the control group.
Study: NCT04455711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Continuous infusion of remifentanil 1.5 ng/ml until extubation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Continuous infusion of remifentanil 1.5 ng/ml until extubation
Study: NCT03668574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise that is defined as a form of exercise lasting 15 to 60 minutes continuous and intensity of 60% to 90% of maximal heart rate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Will be treated with pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes. The devices will be used with disconnected internal cables to obtain the placebo effect
Study: NCT01671280

Intervention type: DRUG
Intervention: Azithromycin IV
Description: The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.
Study: NCT02299960

Intervention type: DEVICE
Intervention: Endo-PAT
Description: Analysis of endothelial function through pulse-amplitude-tonometry

Intervention type: DEVICE
Intervention: Endo-PAT
Description: Analysis of endothelial function through pulse-amplitude-tonometry

Intervention type: DEVICE
Intervention: Endo-PAT
Description: Analysis of endothelial function through pulse-amplitude-tonometry

Intervention type: DEVICE
Intervention: Endo-PAT
Description: Analysis of endothelial function through pulse-amplitude-tonometry

Intervention type: DEVICE
Intervention: NICOM
Description: Non-invasive measurement of cardiac output

Intervention type: DEVICE
Intervention: NICOM
Description: Non-invasive measurement of cardiac output
Study: NCT00622895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given PO
Study: NCT00027872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00536393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin pegylated
Study: NCT02671513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
Study: NCT00185198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testogel (Testosterone, BAYV001915)
Description: 50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
Study: NCT04386759

Intervention type: OTHER
Intervention: Cohort
Description: None. Only implementation of a cohort with data collection via individual self-questionnaires and administrative services for contextual data.
Study: NCT01925092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: tablets
Study: NCT01885455

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care includes: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: The proposed Intervention (EPDPN) will be administered by the PNs at the intervention sites on an outpatient basis. Several defining, fundamental characteristics of the PNs will ensure consistency of the intervention delivery across the various study sites.
Study: NCT01612520

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telecoaching
Description: The COACH program trains patients to 'drive' the process of achieving and maintaining the target levels for their risk factors while working in association with their GP. The telephone coaching is aimed at improving self-efficacy by adhering to the prescribed therapy and making relevant behavior changes.~The coaching model is a continuous five-stage coaching cycle: Stage 1. Finding out what the patient knows; Stage 2. Telling the patient what they should know; Stage 3. Assertiveness training; Stage 4. Setting an action plan; Stage 5. Reassessment at the next coaching session (monitoring).~The coach monitors and registers: the biomedical risk factors, the lifestyle/behavioral risk factors and use of the recommended medications. Coaching is focused on eliminating the knowledge gap and motivating the patient to apply the appropriate lifestyle and medical therapy.
Study: NCT02359617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin delivery
Description: Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glucose sensing
Description: Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
Study: NCT02754622

Intervention type: OTHER
Intervention: Observational Group
Description: Indirect calorimetry measurement during Physical Rehabilitation. Observing planned physical rehabilitation session to determine the rehabilitation activity achieved with IC utilised to determine the number of calories used per session
Study: NCT01270919

Intervention type: DEVICE
Group type: OTHER
Intervention: BioDuct Meniscal Repair Device
Description: The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.~The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear.
Study: NCT00660647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
Study: NCT02615847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantinhydrochlorid
Description: Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.~The study drug will be taken once a day per os, during 12 month.